AdvaMed® Response to Senate HELP Committee Regarding Reauthorization of Pandemic All-Hazards Preparedness Act
On March 29, AdvaMed® responded to the Senate HELP Committee’s request for information on policy priorities for the reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA). The submission includes a set of comprehensive recommendations to enhance national preparedness and response efforts for public health emergencies. We also outline policies that would bolster public health infrastructure, as well as coordination between the federal government and industry stakeholders.
Related Reading
News / Diagnostics / Medical Imaging / Regulatory Affairs
Cubresa Announces FDA 510(k) Clearance for the Cubresa BrainPET™ Scanner, Opening New Frontier in Clinical Brain Imaging
August 20, 2026
WINNIPEG, MANITOBA, CANADA, August 20, 2026 /EINPresswire.com/ — Cubresa Inc., a global leader in clinical and preclinical molecular imaging technologies, today announced that it has received FDA 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its groundbreaking Cubresa BrainPET™ scanner.
News / Diagnostics / Digital Health / Government & Legislative Affairs / Regulatory Affairs
AdvaMed Statement on the Nomination of Dr. Heidi Overton as FDA Commissioner
August 19, 2026
WASHINGTON—Scott Whitaker, president and CEO of AdvaMed, the medtech association, made the following comment on President Trump’s nomination of Dr. Heidi Overton to serve as FDA commissioner.
News / Government & Legislative Affairs / Regulatory Affairs / Small Business
AdvaMed Names Juan Carlos “JC” Scott Chief Strategy Officer and Executive Director of AdvaMed Accel
August 12, 2026
WASHINGTON, D.C. – AdvaMed today announced that Juan Carlos “JC” Scott has been appointed Chief Strategy Officer and Executive Director of AdvaMed Accel, a newly created leadership position focused on accelerating engagement with emerging medical technology companies and strengthening AdvaMed’s role at the center of the innovation ecosystem.
Resource / Government & Legislative Affairs
Scott Whitaker Op-Ed: Medtech: A great value in American health care
August 7, 2026
Medicare breakthrough medical technologies face delays between FDA authorization and coverage decisions, slowing patient access to innovation.
Event / AdvaMed Advancements / Business Development / Government & Legislative Affairs / Regulatory Affairs / Small Business
AdvaMed® Medtech Showcase
September 16, 2026
5:00 PM – 7:00 PM
Experience the future of health care at the 2026 Medtech Showcase and Reception on Capitol Hill. Join AdvaMed® on September 16 for an interactive event featuring more than 25 medtech companies demonstrating breakthrough technologies that are transforming patient care. See innovative medical devices firsthand, connect with industry leaders and policymakers, and discover how medtech innovation is improving and saving lives.
News / Government & Legislative Affairs / Regulatory Affairs
AdvaMed Strongly Supports Draft MDUFA VI Agreement at FDA Public Meeting
August 5, 2026
WASHINGTON, D.C.—AdvaMed, the Medtech Association, today expressed strong support for the draft Medical Device User Fee Amendments (MDUFA) VI agreement at an FDA public hearing.
Resource / Coverage & Payment / Government & Legislative Affairs / Health Access
Gateways to Health: How Medtech Is Improving Care While Lowering Healthcare Costs
July 31, 2026
Read Gateways to Health, a special publication exploring how medical technology improves patient care, expands access, and lowers healthcare costs.
Blog / Artificial Intelligence (AI) / Diagnostics / Digital Health / Health Access
The Insight Series: AI & Digital Health
July 27, 2026
“The Insight Series: AI & Digital Health” features industry experts answering key questions to help inform policymakers and the public about how AI is shaping the future of care delivery. Our latest edition features Jacque Engle, Vice President of Marketing & Communication and Juli Goldstein, Vice President of Government Affairs & Market Access at Digital Diagnostics.